The intellectual structure and emerging trends on nanotechnology in inflammatory bowel disease: A bibliometric
Lei Liang1, Dexin Wang1, Xiubi Zhang1
1College of Integrative Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan, China.
Background:
As a chronic inflammatory disease of the intestine, inflammatory bowel disease (IBD) is challenged by existing treatment methods, such as poor drug targeting, low bioavailability, and systemic toxicity. In recent years, nanotechnology has provided a new strategy for the treatment and diagnosis of IBD due to its advantages of precise delivery, controllable release and multifunctional integration.
Methods:
We searched the Web of Science Core Collection database for relevant literature about nanotechnology and IBD published from 2005 to 2024. We used SciExplorer, VOSviewer, and Citespace to analyze countries, institutions, authors, keywords, highly cited references, and co-cited references to discuss research hotspots and trends in this field.
Results:
The research analysis included a total of 959 pieces of literature, with China and the USA leading in the number of papers published and academic influence. The Georgia State University had the most papers posted. Merlin Didier and Xiao Bo were the scholars who published the most. The research hotspots mainly focus on nanodrug delivery systems, targeted therapy and inflammation regulation, while exosomes, macrophage polarization, and intestinal microbiota regulation are becoming new research frontiers. In the future, intelligent responsive nanomaterials, multifunctional nanoplatforms, and personalized nanotechnology will become important development directions.
Conclusion:
A new avenue for the accurate diagnosis and treatment of IBD has been unlocked by nanotechnology, but its clinical translation needs to break through the bottlenecks of biocompatibility, large-scale preparation and interdisciplinary collaboration. In the future, we should focus on the development of "intelligent responsive nanosystems," deepen the research on the interaction mechanism of "nano-microbe-host," and promote the establishment of a personalized treatment system.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
